were performed using standard procedures.
Seven patients had IgG MGUS except for 1 who had IgA MGUS.
The serum M-protein of all patients were ≥1.5 g/dL (median 2.6 g/dL, 
CONFLICT OF INTEREST
Nothing to report. ing. 4 However, individuals with prior stroke or cerebral vasculopathy must remain on indefinite CRCT for optimal stroke prevention. 5 Despite these guidelines, CRCT is likely underutilized. 3 Barriers to CRCT implementation are likely multi-factorial, involving multiple patient and health care factors (eg, transition to adult care, socioeconomic/ geographic variables). 6 No prior studies have examined barriers to lifelong CRCT implementation in individuals with SCD at high stroke risk.
This study's goals were to: (i) describe the CRCT status of patients with SCD at high stroke risk in a large, Southeastern urban clinic and
(ii) examine differences in patient-level characteristics related to CRCT implementation. We hypothesized that age, provider type, and proximity to comprehensive care would be associated with CRCT utilization. Patient characteristics were compared based on CRCT status using one-way ANOVA and Chi-square tests or Fisher's Exact tests (Table 1) . Age was examined as a confounding variable using Chisquare tests or Fisher's Exact tests, and logistic regression was used to examine specific characteristics and CRCT status adjusting for variables confounded by age. Analyses were conducted in SAS version 9.4; significance level α was maintained at 0.05.
We identified 143 patients with SCD at high stroke risk, 9%
(13 patients) of whom were confirmed deceased. Of these patients, 52%
(68/130) were being treated with CRCT, 24% (31/130) were off CRCT therapy, and 24% (31/130) were LTFU. Initial treatment indication included: prior stroke (n = 81), abnormal TCD (n = 39), subarachnoid hemorrhage (n = 2), abnormal brain imaging (n = 3), seizure (n = 1), and multiple neurological indications (n = 1). The majority of patients not on CRCT (74%; 23/31) had CRCT stopped by provider choice, of whom 57% (13/23) were started on Hydroxyurea. These individuals had been receiving CRCT for greater than 5 years (exact duration is unknown) prior to termination. Historical encounters indicate some concern for iron overload in many patients, but not as the reason for stopping transfusion.
No concerns for alloimmunization were noted. Further, many of these individuals had not undergone updated neuroimaging to assess for cerebrovascular changes. Patients currently on CRCT were significantly younger than patients off therapy or those LTFU. Over 91% of patients on CRCT had a SCD specialist versus 45% not on CRCT (P < .0001).
Region did not differentiate those on CRCT versus off therapy; however, the majority of patients LTFU lived outside the Tri-County (P = .005).
Results for CRCT indication showed 62% of patients on CRCT had prior stroke compared with 48% not on CRCT and 77% LTFU (P = .020).
There were no significant differences for insurance status (P = .072).
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